ChemoMetec revenue rises 3%, EBITDA margin improves
ChemoMetec said revenue increased 3% to DKK 511 million, helped by strong XcytoMatic instrument sales, and EBITDA margin improved to 55%.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.